Long-term extension study of tofacitinib in refractory dermatomyositis

Arthritis Rheumatol. 2022 Feb;74(2):371-372. doi: 10.1002/art.41944. Epub 2021 Dec 28.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dermatomyositis / drug therapy*
  • Humans
  • Piperidines / therapeutic use*
  • Prospective Studies
  • Pyrimidines / therapeutic use*
  • Time Factors

Substances

  • Piperidines
  • Pyrimidines
  • tofacitinib